RxDoctor Payments Data

David Chun, MD

Internal Medicine · Newport Beach, CANPI 1730152976

Payments from drug & device makers

$4,565in general payments, 2019–2025

Across 214 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$746
  • Amgen$726
  • AstraZeneca$288
  • Pfizer$288
  • Lilly USA, LLC$273
  • GSK$268
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,48598%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,565 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$192,264
Medicare patients
315
Services billed
4,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$109,076
Wellbutrin XlBupropion Hcl19$42,184
JardianceEmpagliflozin23$22,075
JanuviaSitagliptin Phosphate18$19,799
OzempicSemaglutide18$15,628
Repatha SureclickEvolocumab24$14,660
XareltoRivaroxaban15$11,367
MyrbetriqMirabegron17$10,274
LinzessLinaclotide15$9,538
CreonLipase/Protease/Amylase11$8,857
Testosterone24$7,631
PremarinEstrogens, Conjugated13$5,850
Levothyroxine Sodium257$4,095
SynthroidLevothyroxine Sodium52$3,918
Atorvastatin Calcium418$3,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$288$116,356186 claims
AbbVieLinzess, Creon, Synthroid$746$22,31278 claims
Boehringer IngelheimJardiance$16$22,07523 claims
MerckJanuvia$246$19,79918 claims
Novo NordiskOzempic$235$15,62818 claims
Johnson & JohnsonXarelto$107$11,36715 claims
Astellas Pharma US IncMyrbetriq$246$10,27417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →